The authors regret making a spelling error in Carmen Blanco‐Aparicio's name. The spelling is herewith corrected.
. 2020 Jan 9;12(1):e11749. doi: 10.15252/emmm.201911749
Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
Sofie Mohlin
, Karin Hansson
, Katarzyna Radke
, Sonia Martinez
, Carmen Blanco‐Aparicio
, Cristian Garcia‐Ruiz
, Charlotte Welinder
, Javanshir Esfandyari
, Michael O'Neill
, Joaquin Pastor
, Kristoffer von Stedingk
, Daniel Bexell
Sofie Mohlin
Find articles by Sofie Mohlin
Karin Hansson
Find articles by Karin Hansson
Katarzyna Radke
Find articles by Katarzyna Radke
Sonia Martinez
Find articles by Sonia Martinez
Carmen Blanco‐Aparicio
Find articles by Carmen Blanco‐Aparicio
Cristian Garcia‐Ruiz
Find articles by Cristian Garcia‐Ruiz
Charlotte Welinder
Find articles by Charlotte Welinder
Javanshir Esfandyari
Find articles by Javanshir Esfandyari
Michael O'Neill
Find articles by Michael O'Neill
Joaquin Pastor
Find articles by Joaquin Pastor
Kristoffer von Stedingk
Find articles by Kristoffer von Stedingk
Daniel Bexell
Find articles by Daniel Bexell
Issue date 2020 Jan 9.
© 2019 The Authors. Published under the terms of the CC BY 4.0 license
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
PMCID: PMC6949485 PMID: 31916402
This corrects the article "Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma" in volume 11, e10058.